News

NDA Clinical Briefing Package Submitted to the US FDA

Melbourne (Australia) – 27 Dec 2019. Telix Pharmaceuticals Limited is pleased to announce that it has submitted a complete clinical briefing package to the US FDA for its first product TLX591-CDx1

Melbourne (Australia) – 27 Dec 2019

Telix Pharmaceuticals Limited (ASX: TLX), is pleased to announce that it has submitted a complete clinical briefing package to the US FDA for its first product TLX591-CDx1, following the procedural guidance received from its pre-NDA2 meeting (reported 28th August 2019).

Telix has also completed the additional manufacturing and product release analytics that were recommended by the FDA. Consequently, the amended Drug Master File (DMF) will be filed with the FDA during January 2020 as part of the company’s ongoing NDA submission process.

To read the full media release click here.

More Articles

News

NDA Clinical Briefing Package Submitted to the US FDA

Melbourne (Australia) – 27 Dec 2019. Telix Pharmaceuticals Limited is pleased to announce that it has submitted a complete clinical...

News

TLX101 for Brain Cancer IPAX-1 Study Update

Melbourne (Australia) – 23 December 2019. Telix Pharmaceuticals has released an update on the progress of its TLX101 product being...

News

ZIRCON Phase 3 IND Submitted to the US FDA

Melbourne (Australia) – 24 December 2019. Telix Pharmaceuticals Limited is pleased to announce that it has submitted a Phase 3...

News

University of Melbourne collaboration with Telix receives Cancer Australia research grant

Melbourne (Australia) – 19th December 2019. Telix Pharmaceuticals Limited (ASX: TLX) is pleased to announce that Telix collaborator Professor Frédéric...

News

Telix Pharmaceuticals and ATONCO Partner for Bladder Cancer

Melbourne (Australia) and Nantes (France) – 16, Dec 2019. Telix Pharmaceuticals Limited and French company ATONCO S.A.S today announce that...

News

Webcast of CEO’s presentation to Jefferies 2019 London Healthcare Conference

Melbourne (Australia) – 25th November 2019. Telix Pharmaceuticals Limited has today announced that Group CEO, Dr Christian Behrenbruch, presented at...

Corporate Spotlight

Anthony Zinno, MBA Joins Telix Pharmaceuticals US

January 7, 2020 - Telix Pharmaceuticals is pleased to announce the addition of Anthony Zinno to our US Team!

Corporate Spotlight

Robyn Jackson, MBA, CNMT Joins Telix Pharmaceuticals US

January 7, 2020 - Telix Pharmaceuticals is pleased to announce the addition of Robyn Jackson to our US Team!